Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 AND CHILDREN: COMPLICATIONS AND LATE OUTCOMES.

Georgian medical news·2021
Same author

[IMERSLUND-GRÄSBECK SYNDROME CONGENITAL FORM OF VITAMIN B12 DEFICIENCY ANEMIA].

Georgian medical news·2019
Same author

[CONGENITAL DEFICIENCY OF COAGULATION FACTOR V].

Georgian medical news·2016
Same author

[Erythrocyte membrane abnormalities - hereditary elliptocytosis].

Georgian medical news·2015
Same author

[The pure red cell aplasia in children (observation 2010-2012 years)].

Georgian medical news·2013
Same author

Management options for rare diseases in children and adolescents in Georgia (experience of the country with transitional economy).

Georgian medical news·2011

Related Experiment Video

Updated: May 26, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

[Neutropenia in children].

M Kvezereli-Kopadze, A Kvezereli-Kopadze, Z Mtvarelidze

    Georgian Medical News
    |December 14, 2011
    PubMed
    Summary

    Pediatric neutropenia, a decrease in neutrophils, can be mild or severe. This study observed three infants with persistent, severe neutropenia, diagnosing two with benign chronic neutropenia and one with autoimmune neutropenia.

    Area of Science:

    • Pediatrics
    • Hematology
    • Immunology

    Background:

    • Neutropenia in children involves a neutrophil count below 1x10^9/L.
    • While often mild and transient, severe and chronic forms present diagnostic challenges and variable prognoses.
    • Common causes include infections, medications, and nutritional deficiencies, alongside hereditary and congenital origins.

    Observation:

    • This study details observations of three pediatric patients presenting with persistent, severe neutropenia within their first year of life.
    • Clinical and paraclinical data, alongside case history and follow-up, were analyzed.
    • The observation period is ongoing.

    Findings:

    • Two patients were diagnosed with benign chronic neutropenia.
    • One patient was diagnosed with primary autoimmune neutropenia.

    More Related Videos

    A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
    05:35

    A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

    Published on: January 19, 2024

    Related Experiment Videos

    Last Updated: May 26, 2026

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
    05:52

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

    Published on: May 12, 2023

    A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
    05:35

    A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

    Published on: January 19, 2024

  • The findings highlight diagnostic considerations for severe pediatric neutropenia.

    • Implications:

    • Early and accurate diagnosis of severe pediatric neutropenia is crucial for appropriate management.
    • Distinguishing between benign and autoimmune forms impacts long-term prognosis and treatment strategies.
    • Further observation is needed to fully understand the long-term outcomes for these patients.